InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
Professor Hans Clevers, Professor Henning Walczak and Professor Christopher Chen will join the InFLAMES Flagship as visiting professors and lend their expertise to strengthen the Turku-based research and innovation endeavor.
The InFLAMES Flagship (Innovation Ecosystem based on the Immune System) is a joint effort of University of Turku and Åbo Akademi University aiming at being an internationally recognized, top-level, immunological research and development cluster which will be globally attractive both for the researchers and business partners.
The doctoral module of the InFLAMES Flagship (Innovation Ecosystem based on the Immune System) offers immunological and immunology-related education to the doctoral candidates in the Flagship. On this website you can find information regarding the contents, completion and application process of the doctoral module.
Please note that many of the practicalities regarding the module are still being finalized and these sites are expected to be updated frequently.
Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body’s phagocytes and facilitates extensive activation of the immune system.
Although vaccination programmes against pertussis are very effective in Europe, new Finnish study shows that the disease is still very common among middle-aged adults in various European countries. At the same time, the results show that the disease is underdiagnosed as the annually reported figures are considerably lower than those discovered in the study.
The joint immunology flagship effort of the University of Turku and Åbo Akademi University is recruiting over 20 top experts. With the recruitments, the InFLAMES Flagship strengthens its role as the centre for top-level immunology research and development.
This year, the Elias Tillandz prize for the best scientific paper published in 2019 in BioCity Turku has been awarded to Academician Sirpa Jalkanen and her research group.
Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program. With a total funding of 10 million euros, Cancer IO is a significant IO focused Nordic research and innovation program.